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ʹXRCC1 is a molecular scaffold protein that assembles multi-protein 
complexes involved in DNA single-strand break repair1,2. Here, we show 
that biallelic mutations in human XRCC1 are associated with ocular motor 
apraxia, axonal neuropathy, and progressive cerebellar ataxia. XRCC1-
mutant patient cells exhibit not only reduced rates of single-strand break 
repair but also elevated levels of protein ADP-ribosylation; a phenotype 
recapitulated in a related syndrome caused by mutations in the XRCC1 
partner protein PNKP and implicating hyperactivation of poly (ADP-ribose) 
polymerase/s as a cause of cerebellar ataxia. Indeed, remarkably, genetic 
deletion of Parp1 rescued normal cerebellar ADP-ribose levels and reduced 
the loss of cerebellar neurons and ataxia in Xrcc1-defective mice, 
identifying a molecular mechanism by which endogenous single-strand 
breaks trigger neuropathology. Collectively, these data establish the 
importance of XRCC1 protein complexes for normal neurological function 
and identify PARP1 as a therapeutic target in DNA strand break repair-
defective disease. 
 A forty-seven year old woman of East Indian descent and non-
consanguineous parents was diagnosed at age forty-one with cerebellar atrophy, 
gait and limb ataxia, ocular motor apraxia, and peripheral neuropathy (Fig. 1a, b). 
Prenatal and early developmental history was completely normal and difficulties 
with balance and gait were first noticed at twenty-eight years, but this was not 
fully investigated until age forty. Magnetic resonance imaging (MRI) and 
cerebellar examination revealed progressive cerebellar atrophy (Fig. 1c) and 
multiple ataxic abnormalities including dysmetria, dysdiadochokinesis, and 
dysarthria, and nerve conduction studies revealed chronic length-dependent 
sensory-motor predominantly axonal peripheral neuropathy (Fig. 1b, 
Supplementary Information). After ruling out more than ten known spinocerebellar 
ataxias by genetic and metabolic screening (Supplementary Information) exome 
sequencing of the proband identified compound heterozygous mutations in 
XRCC1 (NM_006297). The mutations were confirmed by Sanger sequencing as 
c.1293G>C (p.K431N) and c.1393C>T (p.Q465*) and were present in trans, with 
the unaffected sibling of the proband heterozygous for c.1293G>C (Fig. 1d). 
c.1393C>T has not previously been described in the population, whereas 
͵c.1293G>C was previously detected in heterozygous state in four individuals of 
South Asian descent (ExAC Consortium, Cambridge, MA). After ruling out other 
rare gene variants on the basis of their presence in the unaffected sibling, 
presence in homozygous state in unaffected in-house controls and/or ExAC, and 
lack of functional and/or disease relevance no other candidate causative 
mutations remained. 
The c.1393C>T mutation is located within exon 12 and creates a 
premature stop codon at amino acid 465, most likely triggering nonsense 
mediated mRNA decay. The c.1293G>C mutation is located at the end of exon 
11 and is also part of the donor splice site for intron 11, most likely affecting 
splicing and inducing premature stop codons/nonsense-mediated decay and/or 
encoding XRCC1 with the missense mutation, K431N. Consistent with this, 
reduced total levels of XRCC1 mRNA were observed in patient cells, as well as 
aberrant splicing of XRCC1 transcripts if nonsense-mediated decay was inhibited 
with cycloheximide (Extended Data Fig. 1).  
To establish the pathogenic impact of the biallelic XRCC1 mutations we 
examined patient fibroblasts and lymphoblastoid cells (LCLs) for levels of XRCC1 
protein by indirect immunofluorescence and Western blotting. The level of 
XRCC1 in the patient primary fibroblasts was greatly reduced when compared to 
wild type primary human fibroblasts (1BR) by indirect immunofluorescence and 
was not measurably higher than in human RPE-1 cells in which XRCC1 was 
deleted by CRISPR-Cas9 (Fig. 2a). However, Western blotting suggested that 
patient fibroblasts and LCLs both retained a small amount (~5%) of residual 
XRCC1 (Fig. 2b, Extended Data Fig. 2a). Indeed, this was confirmed using 
XRCC1 siRNA, which reduced the anti-XRCC1 signal on Western blots of patient 
fibroblasts even further (Fig. 2b, bottom). Levels of DNA ligase III (Lig3) were 
also greatly reduced (by >80%) in patient cells, consistent with the established 
impact of XRCC1 on the cellular stability of this partner protein (Fig. 2b, top, 
Extended Data Fig. 2b)3-5. Since germ-line deletion of Xrcc1 in mouse is 
embryonic lethal6 we suggest that the small amount of XRCC1 remaining in the 
patient was important for embryonic viability. Consistent with this idea, embryonic 
viability in mice is supported by a little as ~10% of normal Xrcc1 levels7. 
ͶTo determine whether the residual XRCC1 in patient cells can engage in 
single-strand break repair (SSBR) we quantified the extent to which it bound 
oxidised chromatin. XRCC1 was primarily detected in nucleoli in undamaged wild-
type RPE-1 cells and normal primary 1BR fibroblasts, following the extraction of 
soluble proteins with detergent, but was rapidly recruited into global nuclear 
chromatin following treatment with H2O2 (Fig. 2c, d); a physiological source of 
oxidative single-strand breaks (SSBs)8. In contrast, little or no XRCC1 recruitment 
into chromatin was detected in XRCC1-patient fibroblasts by high-resolution or 
high-content imaging (Fig. 2c, d, Extended Data Fig. 3a). Similar results were 
observed following treatment with camptothecin (CPT), a topoisomerase poison 
that induces SSBs triggered by abortive topoisomerase I activity (Extended Data 
Fig. 3b).  
Importantly, the defect in XRCC1 recruitment in patient fibroblasts was 
accompanied by a delay in the kinetics of DNA single-strand break repair (SSBR) 
following H2O2 treatment (Fig. 3a). This phenotype was recapitulated in XRCC1-/-
RPE-1 cells and is consistent with the established molecular role of XRCC12,9. In 
contrast, we failed to detect a major difference in double-strand break repair in 
XRCC1-patient fibroblasts, as measured by H2AX immunostaining following 
ionising radiation (Fig. 3b, Extended Data Fig. 4). In agreement with the defect in 
SSBR, XRCC1-patient LCLs exhibited a four-fold increase in sister chromatid 
exchange; a hyper-recombination phenotype resulting from elevated homologous 
recombination triggered by unrepaired SSBs in S/G2 phase of the cell cycle (Fig. 
3c)10,11.  
XRCC1 is a scaffold protein that assembles SSBR multi-protein complexes 
and, importantly, components of these complexes are mutated in the cerebellar 
ataxias spinocerebellar ataxia with axonal neuropathy-1 (SCAN1; mutated in 
TDP1)12,13, ataxia oculomotor apraxia-1 (AOA1; mutated in Aprataxin)14, and 
ataxia oculomotor apraxia-4 (AOA4; mutated in PNKP)15,16. Indeed, it is striking 
that the pathology of the XRCC1 patient combines features of each of these 
diseases, consistent with the role played by XRCC1 in coordinating their activity. 
The discovery that XRCC1 is itself mutated in cerebellar ataxia is thus significant 
because it demonstrates the importance of these complexes in preventing 
neurodegeneration in humans.  
ͷTo investigate the mechanism(s) by which unrepaired SSBs trigger 
neuropathology we considered the possibility that persistent unrepaired SSBs 
might result in prolonged activity of the SSB sensor protein, PARP1. This 
hypothesis was prompted by the observation that excessive synthesis of poly 
(ADP-ribose) and/or excessive depletion of NAD+ by PARP1 is neurotoxic and 
associated with ischemia reperfusion injury17,18. Consistent with this idea, whilst 
ADP-ribose was rapidly detected in both wild type and patient fibroblasts following 
H2O2 treatment it persisted at a higher level in the latter cells during subsequent 
incubation in drug-free medium (Fig. 4a, left). This was also evident in XRCC1-/-
human RPE-1 cells, confirming that this phenotype was induced by loss of 
XRCC1. Elevated ADP-ribose levels were also detected in XRCC1 patient 
fibroblasts and XRCC1-/- RPE-1 cells following treatment with camptothecin (CPT) 
(Fig. 4a, right). Indeed, the difference in ADP-ribose levels between wild type and 
XRCC1-mutant cells was even greater following CPT than following H2O2
treatment. The type of SSB induced by CPT has been linked previously with 
SSBR-defective neurodegenerative disease and is a possible source of 
pathogenic SSBs in SSBR-defective individuals13,19. Consistent with this idea, 
CPT-induced ADP-ribose levels were also elevated in fibroblasts from a patient 
with ataxia oculomotor apraxia-4 (AOA4); the cerebellar ataxia resulting from 
mutation of the XRCC1 protein partner, PNKP (Fig. 4b, Extended Data Fig. 5). 
Importantly, the elevated ADP-ribose observed in CPT-treated XRCC1-/- RPE-1 
cells, XRCC1- patient cells, and PNKP-patient cells was entirely dependent on 
PARP1 activity (Fig. 4c, Extended Data Figs 6, 7). Moreover, this phenotype was 
rescued by the introduction of wild-type recombinant XRCC1 into XRCC1 patient 
fibroblasts by electroporation (Fig. 4d, Extended Data Fig. 8).  
Next, to examine directly whether hyperactive PARP1 triggers cerebellar 
ataxia in the absence of efficient SSBR we employed a mouse model in which 
Xrcc1 was conditionally deleted in brain (Xrcc1Nes-Cre)4. Xrcc1Nes-Cre mice exhibit 
pronounced cerebellar histopathology including increased apoptosis of cerebellar 
granule neurons4, greatly reduced numbers of cerebellar interneurons4, and 
decreased electrophysiological spike activity in Purkinje cells (Extended Data Fig. 
9). Moreover, consistent with the pathology of the XRCC1-mutant patient and 
other SSBR-defective patients, Xrcc1Nes-Cre mice exhibit cerebellar ataxia4. 
Strikingly, we detected elevated levels of ADP-ribose in the cerebellum of 
͸Xrcc1Nes-Cre mice suggesting that the loss of Xrcc1 can trigger Parp1 hyper-
activation in brain even at endogenous levels of SSBs (Fig. 4e). Indeed, the 
deletion of Parp1 ablated both the elevated level of ADP-ribose and the 
characteristic loss of cerebellar interneurons in Xrcc1Nes-Cre mice, thereby 
increasing neuronal density in the molecular layer ~4-fold to wild type levels 
(Fig. 5a, b). This did not reflect an impact of Parp1 deletion on the rate of SSBR 
because the latter was similarly slow in XRCC1-/- and XRCC1-/-/PARP1-/- RPE-1 
cells (Extended Data Fig. 10). Rather, these data demonstrate that in the 
absence of Xrcc1-dependent SSB repair Parp1 is hyperactivated, resulting in the 
loss and/or dysfunction of cerebellar neurones. Finally, to examine whether Parp1
deletion also rescued the cerebellar ataxia observed in Xrcc1Nes-Cre mice we 
compared Xrcc1Nes-Cre and Xrcc1Nes-Cre/Parp1-/- mice for their performance on an 
accelerating rotarod. Indeed, remarkably, whereas Xrcc1Nes-Cre mice were 
profoundly ataxic and unable to remain on the rotarod for more than a few 
seconds the additional deletion of Parp1 improved the rotarod performance of 
Xrcc1Nes-Cre mice >30-fold, increasing their mean retention time to ~30 sec 
(Fig. 5c).  
Collectively, these data identify elevated ADP-ribose levels as a biomarker 
of PARP1 hyperactivity and as a cause of cerebellar ataxia induced by unrepaired 
SSBs (Fig. 5d). This scenario might also extend to other more common 
neurodegenerative diseases because elevated levels of oxidative stress and DNA 
strand breakage are also implicated in diseases such as Alzheimer’s disease, 
Huntington’s disease, and Parkinson’s disease20-22.  Finally, these data identify 
PARP1 as a possible drug-target for the treatment of cerebellar ataxias 
associated with unrepaired SSBs. Inhibition of PARP1 with currently available 
chemical inhibitors may not be useful in this context, however, because these 
inhibitors “trap” PARP1 on DNA23 and do not mimic PARP1 genetic deletion 
(Extended Data Fig. 10). However, the development of selective inhibitors of 
PARP1 that prevent DNA binding by this enzyme may have significant 
therapeutic potential. 
Figure Legends 
͹Figure 1. Biallelic XRCC1 mutations are associated with cerebellar ataxia, 
ocular motor apraxia and axonal neuropathy. a, Family pedigree of the 
affected proband (III.1; black circle) and her unaffected sister (III.2; circle with 
black dot). b, Summary of proband clinical features. The full clinical history and 
electrophysiological analysis is presented in Supplementary Information. c, MRI 
of the proband at age 40 and 47. Sagittal T1 weighted images (middle top) 
demonstrating moderately severe vermian atrophy and Axial FLAIR images (right 
top) demonstrating atrophy of the cortex of the vermis and cerebellar 
hemispheres at age 40. Note that imaging at age 47 reveals progression of the 
vermian atrophy and atrophy of the vermian cortex and cerebellar hemispheres 
(bottom). The cerebellum is circled in white and insets (left) are magnifications of 
the sagittal images to highlight the cerebellar atrophy. d, Confirmation by Sanger 
sequencing of the mutations c.1293G>C (p.K431N) and c.1393C>T (p.Q465*) in 
the proband (III.1) and c.1293G>C (p.K431N) in the unaffected sibling (III.2).  
Figure 2. XRCC1 patient mutations greatly reduce XRCC1 protein levels and 
XRCC1 recruitment into damaged chromatin. a, 1BR wild type human 
fibroblasts (“WT Fib.”) and wild type RPE-1 cells (“WT RPE-1”) were compared 
with XRCC1 patient fibroblasts (“Patient Fib.”) and XRCC1-/- RPE-1 cells for 
levels of XRCC1 protein by indirect immunofluorescence. Cells were 
counterstained with DAPI and images captured on a Zeiss microscope. b, Top, 
wild type RPE-1 cells, wild type 1BR fibroblasts, and wild type lymphoblastoid 
cells (“LCLs”) were compared with XRCC1-/- RPE-1 cells, XRCC1 patient 
fibroblasts, and with LCLs from the XRCC1 patient or the unaffected sibling for 
levels of XRCC1, Lig3, and Tubulin by Western blotting. Bottom, wild type or 
patient fibroblasts were transfected with non-targeting or XRCC1 siRNA and 
XRCC1 and Tubulin protein levels analysed by Western blotting. c, XRCC1 
recruitment into chromatin was compared in the indicated cell lines before and 10 
min after treatment with 1 mM H2O2. Cells were pre-extracted with detergent prior 
to fixation and immunostaining, and images were captured as above. d, 
Quantitation of XRCC1 in chromatin (excluding the nucleoli) from >1000 cells per 
sample using Olympus ScanR acquisition and analysis software. Data are the 
mean (+/-1SD) of three independent experiments. Statistical significance (two-
ͺtailed t-test) was assessed where indicated (**p<0.01; “ns”, not significant). 
Representative ScanR images are shown in Extended Data Fig. 3a. Scale bars 
are 10 µm.  
Figure 3. Defective DNA single-strand break repair in XRCC1-mutant patient 
cells. a, DNA strand breakage was quantified by alkaline comet assays in wild 
type RPE-1 cells, XRCC1-/- RPE-1 cells, normal human fibroblasts (1BR), and 
XRCC1-mutated patient fibroblasts before and immediately after treatment with 
H2O2 on ice and after the indicated repair periods in drug-free medium. Data are 
the average comet tail moment (an arbitrary unit-measure of DNA strand breaks) 
of 100 cells per sample and are the mean (+/-SEM) of three independent 
experiments. Statistically significant differences (two-way ANOVA) are indicated 
(*p<0.05; **p<0.01). b, H2AX foci were quantified as a measure of DSBs in the 
indicated cell lines before and at the indicated times after ionising radiation 
(2 Gy). Data are the average number of H2AX foci per cell from ~1000 
cells/sample and are the mean (+/-1SD) of three independent experiments. Data 
were quantified by ScanR high content imaging. Statistically significant 
differences (two-way ANOVA) are indicated (**p<0.01; ns, not significant). 
Representative images are presented in Extended Data Fig. 4. c, Representative 
images (left) and quantification (right) of sister chromatid exchanges in LCLs from 
an unrelated normal control (“WT”), the unaffected sibling, and the XRCC1-
mutated patient. A total of 36 metaphases per genotype were scored and the 
mean number of SCEs (+/-1SEM) per chromosome was plotted for each 
metaphase. Statistically significant differences (two-tailed t-test) are indicated 
(**p<0.01; ns, not significant). Scale bars are 10 µm.  
Figure 4. Elevated ADP-ribosylation in XRCC1-mutated patient cells and 
cerebellum. a, Levels of ADP-ribosylation were measured in 1BR wild type 
human fibroblasts (“WT Fib.”), wild type RPE-1 cells (“WT RPE-1”), XRCC1
patient fibroblasts (“Patient Fib.”), and XRCC1-/- RPE-1 cells by indirect 
immunofluorescence using Anti-pan-ADP-ribose binding reagent (Millipore). Cells 
were treated with 150 µM H2O2 for 10 min and then incubated in drug-free 
medium for 60 min to allow DNA repair or were incubated with 30 µM CPT for 
ͻ45 min. b, Left, ADP-ribosylation was detected in 1BR wild type and PNKP 
patient fibroblasts after CPT treatment by indirect immunofluorescence as above. 
Middle, Western blot showing PNKP, XRCC1, and PARP1 levels in the two cell 
lines. Right, Quantitative comparison of ADP-ribose levels in 1BR wild type, 
XRCC1-mutant patient, and PNKP patient fibroblasts before and after CPT 
treatment, measured by ScanR imaging and plotted relative to the ADP-ribose 
level in untreated 1BR cells. Data are from >1000 cells/sample and are the mean 
(+/-1SD) of three independent experiments. Statistically significant differences 
(two-tailed t-test) are indicated (*p<0.05). c, ADP-ribosylation was detected in 
wild type (“WT”), XRCC1-/-, PARP1-/-, and XRCC1-/-/PARP1-/- RPE-1 cells after 
CPT treatment by indirect immunofluorescence as above. d, Levels of ADP-
ribosylation were quantified before and after CPT treatment by high content 
imaging as above in wild type 1BR fibroblasts, XRCC1 patient fibroblasts (“X1 
pat.”), and XRCC1 patient fibroblasts transfected by electroporation in the 
presence of 1 µg or 2 µg, as indicated, of control BSA or purified recombinant 
human XRCC1-His protein. Statistically significant differences (two-tailed t-test) to 
CPT treated 1BR cells are indicated (*p<0.05). Representative ScanR images are 
presented in Extended Data Figure 8. e, Levels of ADP-ribosylation were 
measured in cerebellar sections from wild type (WT), Xrcc1Nes-Cre (Xrcc1 KO), 
Parp1-/- (Parp1 KO), and Xrcc1Nes-Cre/Parp1-/- (Xrcc1 KO/Parp1 KO) mice by 
immunohistochemistry using rabbit anti-poly (ADP-ribose) primary antibody 
(Trevigen). Scale bars in IF images are 10 µm and in the histology section is 
1 mm.  
Figure 5. Parp1 deletion restores normal interneuron density and reduces 
cerebellar ataxia in XRCC1Nes-Cre mice. a, Neurons in cerebellar sections from 
wild type (WT), Xrcc1Nes-Cre (Xrcc1 KO), Parp1-/- (Parp1 KO), and 
Xrcc1Nes-Cre/Parp1-/- (Xrcc1 KO/Parp1 KO) mice were detected by Nissl staining. 
The position of the granule layer (“gl”), molecular layer (“ml”), and Purkinje cells 
(“pc”) is indicated. Note the reduced number of interneurons (black arrows) in the 
molecular layer of Xrcc1Nes-Cre mice. Representative images are shown and scale 
bars are 200 µm. b, Quantitation of interneuron density in the molecular layer in 
mouse cerebellum of the indicated genotype. Data are the mean (+/-SEM) Nissl-
positive cells per µm2 in the molecular layer of sections from 5-10 mice per 
ͳͲ
genotype. T-test comparisons are indicated (**p<0.01, ***p<0.001). c, Motor 
coordination/cerebellar ataxia was measured in mice of the indicated genotype on 
an accelerating rotarod. The number of mice analysed for each genotype are 
indicated in/above the bars. Statistically significant t-test comparisons are 
indicated (**p<0.01, ***p<0.001). d, Model for PARP1 hyperactivation and neural 
death triggered by unrepaired SSBs. PARP1 binding and activation at SSBs 
results in ribosylation of itself and histones with poly (ADP-ribose) (red wavy 
lines). Poly (ADP-ribose) binding by XRCC1 assembles protein complexes 
containing the enzymes required for repair of the SSBs. However, if SSB repair is 
inefficient, PARP1 activity persists resulting in excessive poly (ADP-ribose) and 
concomitant depletion of NAD+; both of which are implicated in cytotoxicity. 
Protein partners associated previously with cerebellar ataxia in humans are 
highlighted in red and their associated cerebellar ataxias are boxed in red. 
SCAN1; spinocerebellar ataxia with axonal neuropathy-1 (mutated in TDP1). 
AOA1; ataxia oculomotor apraxia-1 (mutated in APTX). AOA4; ataxia oculomotor 
apraxia-4 (mutated in PNKP). We suggest that the patient with XRCC1 mutations 
will be the founder member of a new Syndrome; ataxia oculomotor apraxia-
XRCC1 (AOA-XRCC1), as suggested  in new guidelines for naming movement 
disorders24. 
Methods 
Whole-exome sequencing. Whole-exome library preparation, exon capture and 
sequencing were performed at the Genome Québec Innovation Center (Montréal, 
QC, Canada) as previously described25. Genomic DNA was captured using the 
SureSelect Human 50Mb All Exon kit v5 (Agilent Technologies, Santa Clara, CA, 
USA). Sequencing was performed on an Illumina HiSeq2000 (Illumina, San 
Diego, CA, USA) with paired-end 100-bp reads. A mean coverage of 137x was 
obtained and 97% of the bases were covered at more than 10x. Read alignment, 
variant calling, and annotation were done with a pipeline based on BWA, 
SAMtools, Annovar, and custom annotation scripts. All sequences were aligned 
to Human genome Hg19. We excluded variants with minor allele frequency 
greater than 5% in either the 1000 genomes project 
(http://browser.1000genomes.org/index.html) or the 6500 NHLBI EVS 
ͳͳ
(http://evs.gs.washington.edu/EVS), and seen in more than 30 samples from our 
in-house database (containing approximately 2000 samples). The WES data was 
further filtered to keep protein-damaging variants (nonsense, missense, 
frameshift, indel, and splice variants). 
Antibodies and chemicals. The antibodies employed in this study were anti-
XRCC1 rabbit polyclonal (Millipore; ABC738), anti-Lig3 (TL25) rabbit 
polyclonal26, anti-PNKP (SK3195) rabbit polyclonal27, rabbit Fc-fused Anti-pan-
ADP-ribose binding reagent (Millipore; MABE1016), anti-poly (ADP-ribose) rabbit 
polyclonal (Trevigen; 4336), anti-α-tubulin rat polyclonal (Abcam; ab6160), anti-
BrdU rat monoclonal, crossreacting with CldU, (BioRad; OBT0030G), anti-
nucleophosmin (B23) mouse monoclonal (Invitrogen; 325200), anti-PARP1 
mouse monoclonal (Serotec; MCA1522G) and anti-H2AX mouse monoclonal 
(Millipore; 05-636). The secondary antibodies employed for Western blotting were 
HRP-conjugated goat anti-rabbit (Bio-Rad; 170-6515), goat anti-mouse (Bio-Rad; 
170-6516) and rabbit anti-rat (Abcam; ab6734) and for indirect 
immunofluorescence were goat anti-mouse or anti-rabbit Alexa 488 (Invitrogen; 
A11001 and A31628), goat anti-rabbit Alexa 568 (Invitrogen; A11036), donkey 
anti-mouse Alexa 647 (Invitrogen; A39571) and goat anti-rat Alexa 568 
(Invitrogen; A11077). Camptothecin (CPT) was purchased from Sigma and 
Hydrogen Peroxide (H2O2) was obtained from Fischer Scientific. Veliparib (ABT-
888) was purchased from Selleckchem and KU0058948 hydrochloride from Axon.   
Cell lines. All cell lines were tested for absence of mycoplasma. Wild type human 
hTERT RPE-1 cells (ATCC; CRL4000)(denoted “RPE-1” for simplicity) and their 
XRCC1-/- derivative (XRCC1-/- RPE-1 cells) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM/F12; Sigma) supplemented with 10% fetal calf serum 
and 0.01 mg/ml hygromycin B in a humidified atmosphere of 5% CO2 at 37°C. 
Wild type control cells were 1BR3 (denoted 1BR in the text for simplicity) primary 
human fibroblasts and the lymphoblastoid cell line (LCL) 11-27 isolated from an 
normal unaffected control. XRCC1 patient primary fibroblasts (identifier number; 
5596502b) were generated from a patient skin biopsy and the LCL cell lines 
HEP15-00082 and HEP15-00083 were obtained from fresh blood from, 
ͳʹ
respectively, the unaffected sibling and affected patient by EBV transformation. 
Appropriate patient consent was provided for preparation of primary fibroblasts. 
Primary human fibroblasts from a PNKP-mutated patient with cerebellar ataxia 
have been described previously28. Primary human fibroblasts were grown in 
Minimum Essential Media (MEM; Gibco) containing 15% fetal calf serum, 2 mM 
glutamine, and the antibiotics penicillin (100 units/ml) and streptomycin (100 
μg/ml) at low oxygen (5%) at 37oC. LCLs were cultured in RPMI medium (Gibco) 
containing 10% FBS, 2 mM glutamine and penicillin/streptomycin, in a humidified 
atmosphere of 5% CO2 at 37°C.
Generation of gene edited RPE-1 cells. Guide sequences were identified using 
either E-CRISP (http://www.e-crisp.org/E-CRISP/) or CRISPRdirect 
(http://crispr.dbcls.jp). For XRCC1 gene editing we chose the 23-mer CRISPR 
complementary guide RNA sequences 5’-CCGCCUCCGCCAUGUCGUGUCCU-
3’ & 5’-AGGGACACGACAUGGCGGAGGCGG-3’ (PAM underlined) spanning 
XRCC1 ORF nucleotides 12-34, and employed the 58-
mer synthetic oligonucleotides 
(XCr2F; 5’-TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGACAC
GACATGGCGGAGG & 
XCr2R; 5’-GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCCTCCG
CCATGTCGTGTC) (Eurofins) encoding 18 bp Tru-guide29 versions of the guide 
(underlined) minus the PAM. For PARP1 gene editing we chose the 20-mer ‘Tru-
guide’ sequences 5’-GCACCCUGACGUUGAGGUGG-3’ and 
5’-CCACCUCAACGUCAGGGUGC-3’ (PAM underlined) spanning nucleotides 
195-214 of the human PARP1 ORF, and employed the 57-mer synthetic 
oligonucleotides PARP1-2F: 
5’-TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCACCCTGACG
TTGAGG-3’ & PARP1-2R: 
5’-GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCCTCAACGTCA
GGGTGC-3’ encoding the 17 bp Tru-guide versions of the guide (underlined) 
minus the PAM. 
The relevant oligonucleotide guide pairs were annealed and extended into 
a 98-mer oligonucleotide duplexes using Phusion polymerase (NEB) and then 
subcloned into the guide RNA vector (Addgene; #41824)30 using Gibson 
ͳ͵
Assembly (NEB). hTERT RPE-1 cells were co-transfected with the relevant guide 
construct/s separately (XRCC1-/-, PARP1-/-) or together (XRCC1-/-/PARP1-/-) and 
with the Cas9 expression construct Addgene #4181530 using a NEON 
Transfection System (Invitrogen). 24 h later, the transfected cells were selected in 
medium containing 0.5 mg/ml G418 for 5 days and subcloned into 96-well plates. 
Once at sufficient cell density the subclones were analyzed for expression of the 
relevant protein/s by indirect immunofluorescence. Absence of the relevant 
protein/s in selected clones was then confirmed by Western blotting. For XRCC1-/-
, PARP1-/-, and XRCC1-/-/PARP1-/- RPE-1 cells we selected clones #3, #G7, and 
#D1 for further work, respectively. 
Complementation of XRCC1 patient cells with recombinant XRCC1 protein. 
Recombinant human XRCC1 harbouring a C-terminal decahisitidine tag (denoted 
XRCC1-His) was expressed in E.coli from pET16b-XH and purified by metal-
chelate affinity chromatography and gel filtration3. 1 or 2 µg of control bovine 
serum albumin (BSA) or purified XRCC1-His was electroporated into 1x105
XRCC1 patient fibroblasts using a NEON Transfection System (Invitrogen) 
according to the manufacturer’s protocol. 18 hours later the cells were treated 
with CPT for 45 min, fixed, and immunostained for levels of XRCC1 and ADP-
ribose as indicated. 
RNA extraction, cDNA synthesis and qPCR analysis. LCLs were treated with 
either 100 µg/ml Cycloheximide (Sigma) or vehicle alone for 4 h and total RNA 
extracted with RNAeasy Kit (Qiagen) essentially as described by the 
manufacturer but with an additional 15 min DNAse I (Promega) digest of the 
samples on the column. 1 µg total RNA was annealed to oligodT(15) primer and 
reverse transcribed using M-MuLV RT (NEB) for 2 h at 42°C. After RNAse A 
digest, the cDNA was purified using PCR purification kit (Qiagen) and 1/40 of the 
eluate used per reaction. Three replicate qPCR reactions using ABsolute qPCR 
SYBR Low ROX (Thermo) were performed per experiment in a MX3005P 
(Agilent) thermocycler and analysed using MxPro software (Agilent). The fold 
change was calculated from Ct values relative to actin and Ct values relative 
to WT untreated for three independent experiments. Primers were: 
ͳͶ
XRCC1 exon10 forward: CAACACCCCCAAGTACAGC 
XRCC1 exon 10 reverse: AGTCCAGCACCCACTCCTTAC 
XRCC1 exon11 forward: TCCAGCAGTGAGGAGGATG 
XRCC1 intron11 reverse: AGGCAAGAGTGGGAAGTTTG 
XRCC1 exon 12 reverse: AGTGGGCTTGGTTTTGGTC 
Actin forward: CTCGTCATACTCCTGCTTGC 
Actin reverse: GAAGTGTGACGTGGACATCC 
XRCC1 cDNA cloning. cDNA prepared as above from patient cells treated with 
cycloheximide was used for Phusion polymerase (NEB) amplification of full length 
XRCC1 transcripts using primers ATGCCGGAGATCCGCCTCCG and 
GGCTTGCGGCACCACCCCAT. PCR products were purified using Gel extraction 
kit (Qiagen), cloned using TOPO cloning kit (Thermo Fischer Scientific) and 
plasmids originating from single colonies purified using Miniprep kit (Qiagen) and 
sequenced by Sanger sequencing (Beckman Coulter).  
siRNA. Wild type and patient primary fibroblasts were reverse-transfected with 
Lipofectamine RNA iMAX (Life Technologies) as indicated by the manufacturer, 
using non-targeting siRNA (ON-TARGETplus, Dharmacon) and siXRCC1 
SMARTpool (Dharmacon). 
Western blotting. PBS-washed cells were lysed in Laemmli buffer, heated for 10 
min at 95°C, and sonicated for 30 sec using Bioruptor® Pico (Diagenode). Protein 
concentrations were determined using the BCA assay (Pierce). Samples were 
subjected to SDS PAGE, proteins transferred onto nitrocellulose membrane and 
detected by immunoblotting using the relevant primary and horseradish 
peroxidase-conjugated secondary antibodies. Peroxidase activity was detected 
by ECL reagent (GE Healthcare) and Amersham Hyperfilm ECL (GE Healthcare). 
Non-saturated film exposures were digitalized using an EPSONperfection 2400 
photo scanner and quantified using ImageJ software.  
Immunofluorescence and microscopy. Cells cultured on glass coverslips were 
fixed in 4% paraformaldehyde for 10 min at room temperature, permeabilized in 
methanol/acetone solution (1:1), blocked in 10% foetal calf serum and incubated 
ͳͷ
with primary antibodies for 60 min at room temperature. Following rising in PBS, 
coverslips were incubated with secondary antibodies at room temperature for 
60 min. Finally, after washing in PBS, nuclei were counterstained with DAPI 
(Sigma) and coverslips mounted using anti−fading mounting reagent 
(Vectashield, Vector Laboratories). To measure chromatin retention of proteins, 
cells were pre-extracted in cold 0.2% Triton X-100 for 2 min on ice prior to fixation 
as above. High-resolution microscopy of fixed samples was carried out on a Zeiss 
AxioObserver.Z1 microscope, equipped with oil immersion objectives (Plan-
Apochromat 63x/1.4 and 100x/1.4), Hamamatsu ORCA-Flash4.0 LT camera and 
ZEN 2 core imaging software. Automated wide-field microscopy was performed 
on an Olympus ScanR system (motorized IX83 microscope) with ScanR Image 
Acquisition and Analysis Software, 20x/0.45 (LUCPLFLN 20x PH) and 40x/0.6 
(LUCPLFLN 40x PH) dry objectives and Hamamatsu ORCA-R2 digital CCD 
camera C10600.  
ADP-ribose immunohistochemistry. Mice (P17-P23) were anaesthetized using 
0.2 mg/g Euthanal (Vetoquinol UK Ltd) and perfused transcardially with PBS 
followed by 4% paraformaldehyde. The brains were postfixed in 4% 
paraformaldehyde for 48 h and stored in 25% sucrose/PBS until moulding and 
freezing. 7 μm sagittal sections were obtain using a cryostat (Leica CM1850). 
Immunohistochemistry was conducted essentially as described4. Briefly, slides 
were washed in PBS and heated until boiling in antigen retrieval buffer (Nacalai 
Tesque, Histo VT One). Endogenous peroxidase was blocked by incubating 
slides in 0.6% H2O2 in methanol. After incubating in blocking solution (5% goat 
serum, 1% BSA, 0.4% Triton-X-100 in PBS) the indicated primary antibodies 
were applied on overnight. The appropriate Biotin-SP-conjugated AffiniPure Goat 
antibody (JacksonImmuno Research, 1:500) was incubated on the slides for 1 hr 
followed by ABC reagent (Vectstain Elite ABC kit, Vector Laboratories) according 
to manufacturer’s instructions.  The chromogen was developed using VIP reagent 
(Vector VIP peroxide substrate kit, Vector laboratories, Inc.; SK-4600). Images 
were obtained using a Nikon Eclipse E400 mounted with Electronic Digital 
Eyepiece Camera CMOS (C-mount UK). 
ͳ͸
Sister chromatid exchanges. Lymphoblastoid cell lines were incubated in 
medium containing 8 µM chlorodeoxyuridine, 32 µM thymidine, 10 µM 
fluorodeoxyuridine and 200 µM cytidine (such that 20% of incorporated thymidine 
is replaced with chlorodeoxyuridine)11,31 for 20 h, washed twice in media and then 
allowed to grow for another 20 h in medium containing 10 µM thymidine. Cells 
were treated with 100 ng/ml colcemid for 1 h, swollen in 75 mM KCl for 5 min at 
37°C and fixed in Carnoy’s fixative before preparation of metaphase spreads. 
Slides were allowed to air dry, rehydrated in PBS, incubated in 2 M HCl for 
30 min, washed twice in 100 mM borate buffer pH 8.5 for 10 min and blocked in 
10% foetal calf serum in PBS for 30 min. Further immunofluorescence and 
imaging was performed as above.
SSBR & DSBR assays. Alkaline comet assays were performed essentially as 
described32 and inducing DNA breaks with 50 µM H2O2 (RPE-1 cells) or 25 µM 
H2O2 (primary fibroblasts) for 10 min on ice. For DSB repair assays, cells were 
irradiated with 2 Gy using Gammacell 1000 machine, and H2AX quantified at the 
indicated times, afterwards. 
Mouse maintenance and analysis. Animals were maintained and used under 
the auspices of UK Home Office project licence number 70/8300. The generation 
of Parp1-/- and Xrcc1Nes-Cre mice have been reported previously4,33. Intercrosses 
between Parp1-/- and Xrcc1+/loxp mice were maintained in a mixed C57/Bl6 x S129 
strain and housed on a 12 h light/dark cycle with lights on at 7 am. Temperature 
and humidity were maintained at 21oC (+/-2oC) and 50% (+/-10%), respectively. 
All experiments were carried out under the UK Animal (Experimental Procedures) 
Act, 1986. Genomic DNA was extracted from biopsied tail using the REDExtract-
N-Amp Tissue PCR Kit in accordance to the manufacturer’s instructions 
(Sigma). For Parp1, the following primers were used: PARP1 F1 (5’-GTT GTG 
AAC GAC CTT CTG GG-3’), PARP1 R1 (5’-CCT TCC AGA AGC AGG AGA AG-
3’) and PARP R2 (5’-GCT TCA GTG ACA ACG TCG AG-3’). PCR products were 
generated by an initial denaturation step at 94C for 2 min followed by 35 cycles 
of 94C for 30 s, 54C for 40 s and 72C for 180 s. Xrcc1 was amplified using the 
forward PC1 (5’-TAT GCT TGC TGT ACA GGG ATT GGG-3’) and reverse PC2 
ͳ͹
(5’-TGG ACC ATG AAA AAG CTG TGT GC-3’) primers. A 400 bp cre PCR 
product was generated using the forward Cre-3 (5’-CTG CCA CGA CCA AGT 
GAC AGC-3’) and reverse Cre-4 (5’-ACC TGC GGT GCT AAC CAG CG-3’) 
primers. Both Xrcc1 and Cre PCR products were amplified using the following 
PCR conditions: initial denaturation for 5 min at 94C followed by 35 cycles of 
94C for 30 s, 59C for 45 s and 72C for 45 s.  
Nissl staining of paraffin-embedded sections. Brains were removed at the 
indicated times and placed in 10% neutral buffered formalin (3.7% formaldehyde, 
3.5 g/l NaH2PO4, 6.5 g/l Na2HPO4) for 24 h and then transferred to PBS. Paraffin 
embedding, sagittal sectioning and Nissl staining were carried out by Propath UK 
Ltd (Hereford, UK) and UCL IQPath (Institute of Neurology, London, UK). Briefly, 
deparaffinised sectioned were stained in 0.1% cresyl violet solution (0.1% cresyl 
violet, 0.3% glacial acetic acid) for 3-10 minutes, rinsed in water, then 95% 
ethanol for 30 sto 5 min, 100% ethanol for 2 x 5 min and xylene for 2 x 5 min 
before mounting. Nissl-positive interneurons were counted within three randomly-
selected 16875 µm2 regions of each molecular layer, and the number of cells per 
µm2 was calculated. 
Rotarod analysis. To evaluate motor coordination/cerebellar ataxia, an 
accelerating Panlab Rotarod (Harvard Apparatus Ltd., UK) was used. The 
apparatus was composed of a rod with a diameter of 30 mm divided into five 
opaque methacrylate arnite barriers, separating the rod into five 50 mm sections. 
Mice were trained for three successive attempts on the day prior to assessment. 
For assessment, mice were positioned on the rod facing away from the 
experimenter whilst the rod was stationary. Once activated, the rod accelerated at 
0 to 40 rpm at an acceleration rate of 5 min.  Mice were rested for 15 min 
between each of the three trials and then positioned back on the rod for the next 
assessment. The time spent on the rod was recorded for each mouse and the 
mean time was calculated from the three independent trials. 
Purkinje cell recordings. Vermis parasagittal slices (200 μm) were taken from 
P13-P17 mice using a vibroslicer (VT1200S, Leica Microsystems, Germany) in 
ͳͺ
ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): 125 NaCl, 2.5 
KCl, 25 glucose, 1.25 NaH2PO4, 26 NaHCO3, 1 MgCl2, 2 CaCl2 (bubbled with 
95% O2 and 5% CO2, pH 7.3). Slices were maintained in ACSF at 34-35°C for 45 
min and then at 23-25°C for electrophysiology. Voltage-clamp recordings of 
Purkinje cells were performed in cell-attached mode using a Multiclamp 700A 
amplifier (Molecular Devices) with pipettes (5-7 MΩ) containing 150 mM NaCl. 
Signals were filtered at 10 kHz and digitized at 50 kHz and analysis of spike 
activity performed offline using Clampfit (Molecular Devices).
Data Availability. The datasets generated during and/or analysed during the 
current study are available from the corresponding author on reasonable request.  
Data analysis and statistics. The number of experimental repeats and statistical 
tests (conducted in Excel or GraphPad) are indicated in the relevant figure 
legends. The means of population averages from multiple independent 
experiments (+/-SD) are indicated. Where appropriate, power calculations were 
conducted using online statistical resources. Samples were not blinded but the 
collection and analysis of microscopic data was automated and free of user bias. 
No animals/samples were omitted from data points/data analyses.  
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